Loading...

Home
Stock
CSTL

CSTL Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Forecast Technical Valuation Financials Earnings Should I Buy News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
All US Stocks

AI Strategies

AI Stock Picker
Swing Trading
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

40.055

Open

39.160

VWAP

39.00

Vol

426.00K

Mkt Cap

1.00B

Low

38.200

Amount

17.00M

EV/EBITDA(TTM)

111.00

Total Shares

29.00M

EV

866.00M

EV/OCF(TTM)

14.00

P/S(TTM)

3.00

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.

Show More

Events Timeline

(ET)

2026-01-11

17:20:00

Castle Biosciences Expects 2025 Total Revenue to Exceed $340 Million

2026-01-07 (ET)

2026-01-07

06:50:00

Castellum Re-awarded $49.8M Naval Contract

2026-01-05 (ET)

2026-01-05

09:20:00

Castor Maritime Signs Sale and Leaseback Agreement for M/V Magic Perseus, Financing Amount $15.6 Million

2025-12-19 (ET)

2025-12-19

07:10:00

Castle Biosciences Grants 139,494 RSUs to 83 Employees

2025-12-17 (ET)

2025-12-17

07:10:00

Castle Biosciences Releases New Data Showing DecisionDx-UM and PRAME Outperform Gene Mutation Analysis

News

an image of Globenewswire

01-11Globenewswire

Castle Biosciences Expects 2025 Revenue to Exceed $340 Million

Significant Revenue Growth: Castle Biosciences anticipates total revenue for 2025 to exceed $340 million, surpassing the previously guided range of $327-335 million, reflecting strong performance in its innovative test portfolio and bolstering confidence in future growth.
Surge in Core Test Reports: Total test reports for core revenue drivers increased by 37% in 2025 compared to 2024, with DecisionDx-Melanoma reports reaching 39,083 and TissueCypher reports at 39,014, indicating a robust recovery in market demand.
Successful New Test Launch: The limited access launch of AdvanceAD-Tx in November 2025 saw over 50% of 150 clinician offices placing orders within the first five weeks, demonstrating rapid market acceptance and further expanding the company's total addressable market.
Strong Financial Position: Year-end 2025 cash and cash equivalents are expected to be approximately $300 million, alongside $184 million in marketable investment securities, showcasing a solid financial foundation that provides ample funding for future expansion and innovation.

an image of NASDAQ.COM

2025-12-23NASDAQ.COM

AstraZeneca Secures FDA Approval for Enhertu in First-Line Breast Cancer, Triggers $150M Milestone Payment

FDA Approval: AstraZeneca and its partner Daiichi Sankyo's antibody-drug conjugate Enhertu has received FDA approval for first-line treatment of unresectable or metastatic HER2-positive breast cancer, marking a significant milestone in the U.S. market.
Clinical Trial Results: The DESTINY-Breast09 study demonstrated that the Enhertu-Perjeta combination achieved a median progression-free survival of 40.7 months, a 51.5% improvement over the 26.9 months seen with the standard taxane chemotherapy, highlighting its superior efficacy.
Financial Impact: This approval triggers a $150 million milestone payment from AstraZeneca to Daiichi Sankyo, further solidifying their global partnership and providing a new revenue growth avenue for AstraZeneca.
Market Performance: Over the past year, AstraZeneca's stock has surged by 36.3%, significantly outperforming the industry average growth of 12.1%, reflecting strong market confidence in its newly approved drug and future growth potential.

an image of NASDAQ.COM

2025-12-19NASDAQ.COM

Novo Nordisk Submits NDA for Advanced Obesity Treatment CagriSema

Novo Nordisk's New Drug Application: Novo Nordisk has submitted an NDA to the FDA for CagriSema, a once-weekly injection aimed at reducing body weight in adults with obesity or overweight, expected to be reviewed in 2026.
Clinical Study Results: CagriSema demonstrated significant weight loss in two phase III studies, with patients achieving an average weight loss of 22.7% and 15.7% compared to placebo, and a favorable safety profile.
Market Challenges: Despite positive clinical results, Novo Nordisk's stock has declined due to pricing pressures and competition from Eli Lilly's obesity and diabetes drugs, which have rapidly gained market share.
Future Developments: Novo Nordisk is developing additional obesity treatments and expanding its semaglutide franchise, while also pursuing partnerships for new obesity and diabetes therapies.

an image of Globenewswire

2025-12-19Globenewswire

Castle Biosciences Grants 139,494 RSUs to 83 Employees as Inducement

Employee Incentive Program: On December 15, 2025, Castle Biosciences granted 139,494 restricted stock units (RSUs) to 83 employees, aimed at attracting talent and enhancing employee loyalty, which will ultimately improve overall company performance.
Grant Details: These RSUs were awarded under the company's 2022 Inducement Plan and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in three equal installments annually, ensuring continued employee service through each vesting date.
Compliance Assurance: The grant complies with Nasdaq Listing Rule 5635(c)(4), which not only ensures the company's adherence to regulations in attracting and retaining key talent but also boosts investor confidence in corporate governance practices.
Company Vision: Castle Biosciences focuses on improving health through innovative testing, dedicated to providing personalized solutions for dermatologic and gastroenterological diseases, aiming to enhance patient management and treatment outcomes through rigorous science and advanced molecular testing.

an image of Newsfilter

2025-12-19Newsfilter

Castle Biosciences Grants 139,494 RSUs to 83 Employees as Inducement

Employee Incentive Program: On December 15, 2025, Castle Biosciences granted 139,494 restricted stock units (RSUs) to 83 employees, aimed at attracting talent and enhancing employee loyalty, which is expected to improve overall company performance.
Grant Details: The RSUs were awarded under the company's 2022 Inducement Plan and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in three equal installments annually, ensuring continued employee service.
Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to attracting and retaining key talent while enhancing investor confidence through compliance and transparency.
Company Vision: Castle Biosciences focuses on improving health through innovative testing, particularly in dermatologic and gastroenterological diseases, and the RSU grants will further drive the company's strategic goals in personalized healthcare solutions.

an image of Globenewswire

2025-12-17Globenewswire

Castle Biosciences Releases New Data Enhancing Prognostic Accuracy for Uveal Melanoma

Significant Findings: The COOG2 study released by Castle Biosciences indicates that the combination of DecisionDx-UM and PRAME gene expression data significantly enhances predictive accuracy for metastatic risk in uveal melanoma patients compared to individual gene mutation analysis.
Large Sample Size: The study analyzed 1,140 primary uveal melanoma tumors, including 131 early-stage small tumors, providing a comprehensive molecular understanding that aids physicians in making more precise treatment decisions.
Clinical Application Potential: Results show that the DecisionDx-UM + PRAME combination excels in predicting metastasis-free survival and overall survival, which could transform clinical practices and improve patient survival rates.
Market Leadership: Since its introduction in 2009, Castle Biosciences' DecisionDx-UM test has been widely adopted, with nearly 80% of newly diagnosed patients undergoing testing, solidifying its market leadership in prognostic assessment for uveal melanoma.

Wall Street analysts forecast CSTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 47.20 USD with a low forecast of 41.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Analyst Rating

Wall Street analysts forecast CSTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 47.20 USD with a low forecast of 41.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

41.00

Averages

47.20

High

52.00

Current: 0.000

Low

41.00

Averages

47.20

High

52.00

KeyBanc

Paul Knight

maintain

$36 -> $50

AI Analysis

2026-01-29

New

Reason

KeyBanc

Paul Knight

Price Target

$36 -> $50

AI Analysis

2026-01-29

New

maintain

Reason

KeyBanc analyst Paul Knight raised the firm's price target on Castle Biosciences to $50 from $36 and keeps an Overweight rating on the shares.

Guggenheim

Subbu Nambi

maintain

$43 -> $47

2026-01-26

New

Reason

Guggenheim

Subbu Nambi

Price Target

$43 -> $47

2026-01-26

New

maintain

Reason

Guggenheim analyst Subbu Nambi raised the firm's price target on Castle Biosciences to $47 from $43 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CSTL

Unlock Now

Valuation Metrics

The current forward P/E ratio for Castle Biosciences Inc (CSTL.O) is -26.15, compared to its 5-year average forward P/E of -17.63. For a more detailed relative valuation and DCF analysis to assess Castle Biosciences Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-17.63

Current PE

-26.15

Overvalued PE

-3.12

Undervalued PE

-32.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-14.03

Current EV/EBITDA

51.39

Overvalued EV/EBITDA

4.64

Undervalued EV/EBITDA

-32.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

5.82

Current PS

3.52

Overvalued PS

11.61

Undervalued PS

0.03

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best ai stock to buy

Intellectia · 102 candidates

Revenue 5yr Cagr: >= 18Eps 5yr Cagr: >= 12Pe Ttm: <= 35

Ticker

Name

Market Cap$

eToro Group Ltd

3.00B

Brookfield Wealth Solutions Ltd

14.00B

Civitas Resources Inc

2.00B

Futu Holdings Ltd

23.00B

Dlocal Ltd

4.00B

GigaCloud Technology Inc

1.00B

list a stock with 10x potential

Intellectia · 10 candidates

Market Cap: <= 2.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Weekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

Figs Inc

2.00B

Dream Finders Homes Inc

2.00B

Merchants Bancorp

2.00B

Xpel Inc

2.00B

Arhaus Inc

1.00B

GigaCloud Technology Inc

1.00B

stocks that will rise the most by 2026

Intellectia · 17 candidates

Revenue 5yr Cagr: >= 25Eps 5yr Cagr: >= 25Pe Ttm: <= 25Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

Monolithic Power Systems Inc

52.00B

Futu Holdings Ltd

23.00B

Genmab A/S

20.00B

Super Micro Computer Inc

19.00B

Kaspi.kz AO

15.00B

Kinsale Capital Group Inc

9.00B

which stocks should short sell

Intellectia · 2 candidates

Short Ratio: LessThan10PctBeta: HighRiskRsi 14: >= 60Month Price Change Pct: $-100.00 - $0.00

Ticker

Name

Market Cap$

Castle Biosciences Inc

1.00B

Standard BioTools Inc

631.00M

small cap stocks anticipating 20-30% growth

Intellectia · 8 candidates

Market Cap: 300.00M - 2.00BRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

GigaCloud Technology Inc

1.00B

Vital Farms Inc

1.00B

Castle Biosciences Inc

1.00B

LuxExperience BV

1.00B

Nuveen Churchill Direct Lending Corp

678.00M

Tiptree Inc

654.00M

small cap , growth

Intellectia · 18 candidates

Market Cap: 300.00M - 2.00BRevenue 5yr Cagr: >= 10Eps 5yr Cagr: >= 10Pe Ttm: <= 30Annual Revenue Yoy Growth: >= 15.0%

Ticker

Name

Market Cap$

Costamare Inc

2.00B

Dream Finders Homes Inc

2.00B

Merchants Bancorp

2.00B

GigaCloud Technology Inc

1.00B

Vital Farms Inc

1.00B

Opera Ltd

1.00B

Next stock that will 100x

Intellectia · 7 candidates

Market Cap: <= 2.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Pe Ttm: <= 20

Ticker

Name

Market Cap$

Dream Finders Homes Inc

2.00B

Merchants Bancorp

2.00B

GigaCloud Technology Inc

1.00B

Opera Ltd

1.00B

Castle Biosciences Inc

1.00B

Inmode Ltd

893.00M

Best stocks to 1000x in future

Intellectia · 21 candidates

Market Cap: <= 5.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20

Ticker

Name

Market Cap$

Crocs Inc

4.00B

St Joe Co

4.00B

Paymentus Holdings Inc

4.00B

ACM Research Inc

3.00B

Fortuna Mining Corp

3.00B

Banc of California Inc

3.00B

Best stock with future potential 100x

Intellectia · 7 candidates

Market Cap: <= 2.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Pe Ttm: <= 20

Ticker

Name

Market Cap$

Dream Finders Homes Inc

2.00B

Merchants Bancorp

2.00B

GigaCloud Technology Inc

1.00B

Opera Ltd

1.00B

Castle Biosciences Inc

1.00B

Inmode Ltd

893.00M

Whales Holding CSTL

Summit Partners Public Asset Management, LLC

Portolan Capital Management, LLC

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is Castle Biosciences Inc (CSTL) stock price today?

The current price of CSTL is 39.39 USD — it has increased 0.59 % in the last trading day.

What is Castle Biosciences Inc (CSTL)'s business?

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.

What is the price predicton of CSTL Stock?

Wall Street analysts forecast CSTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is47.20 USD with a low forecast of 41.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Castle Biosciences Inc (CSTL)'s revenue for the last quarter?

Castle Biosciences Inc revenue for the last quarter amounts to 83.00M USD, decreased -3.19 % YoY.

What is Castle Biosciences Inc (CSTL)'s earnings per share (EPS) for the last quarter?

Castle Biosciences Inc. EPS for the last quarter amounts to -0.02 USD, decreased -125.00 % YoY.

How many employees does Castle Biosciences Inc (CSTL). have?

Castle Biosciences Inc (CSTL) has 761 emplpoyees as of January 31 2026.

What is Castle Biosciences Inc (CSTL) market cap?

Today CSTL has the market capitalization of 1.00B USD.